Introduction
Idiotopes (Id) are antigenic determinants localized to the V-regions of Ig. Because Ig Vregions are extremely diverse, the monoclonal Ig produced by a malignant B cell clone express unique Id that may function as highly tumorspecific antigen.
Immunization with monoclonal Ig can induce Id-specific antibodies 1 and Id-specific T cells 2 , and early animal experiments suggested that both these humoral and cellular arms of lymphoma in the absence of T cells 16 . The converse, i.e. effect of Id-specific T cells in the absence of antibodies, has been shown in a myeloma model 17 but there is no conclusive evidence for B lymphomas. This is not a trivial distinction as B-cell lymphomas generally express Major Histocompatibility Complex (MHC) class II molecules and surface Ig, both of which myeloma cells lack. Thus, B lymphomas could, in contrast to myeloma cells, be direct targets for both Id-specific CD4 + T cells and antibodies.
Id-specific T cells can be of the CD4 + type recognizing Id-peptide on MHC class II molecules 18, 19 or the CD8 + type recognizing Id-peptide on class I molecules 20, 21 . However, the role of either of these two types of Id-specific T cells in fighting B lymphoma in vivo is poorly understood.
In a BALB/c mouse model, Id-specific CD4 + T cells have been shown to recognize a CDR3 peptide spanning residues 91-101of a 2 Ig L-chain. The particular 2 chain is called 2 315 because it is derived from the MOPC315 plasmacytoma. 2 315 contains unique amino acids in positions 94, 95 and 96, due to somatic mutations in the V-gene segment of MOPC315. T cell recognition of the 2 315 Id heavily depends on these three CDR3 amino acids, and recognition is MHC class II (I-E d ) restricted 18, 22, 23 . In order to establish a lymphoma model, the 2 315 gene was transfected into the BALB/c A20 B lymphoma cells.
Transfected cells (F9) expressed the 2 315 L-chain together with the endogenous H-chain in the cell surface BCR. Moreover, F9 cells spontaneously processed 2 315 and presented the Idpeptide on their class II molecules to cloned Id-specific CD4 + cells 24, 25 . This finding was corroborated by elution of V-region peptides from B lymphoma class II molecules 26 . Thus, B lymphoma cells constitutively express both serologically defined Id (i.e. surface Ig) and T cell defined Id (i.e. Id-peptides on class II molecules), each of which could be targets for Idspecific antibodies and CD4 + T cells, respectively.
Id + F9 B lymphoma cells were rejected by cloned Id-specific T cells in vivo in a Winntype assay 6 . Moreover, Id-specific T cell receptor (TCR)-transgenic mice were protected against challenges with the Id + B lymphoma 27 . However, a role of antibodies or CD8 + T cells was not ruled out in these experiments. Moreover, as rearrangements of endogenous TCRchains are common in TCR-transgenic mice, a considerable TCR repertoire for other antigens than Id could have contributed to this protection.
To overcome these previous limitations, we have now employed recombination- 
Materials and methods

Mice
Mice transgenic for an Id-specific TCR on a BALB/c background have been described 28 25 . To obtain single cell suspensions from ex vivo s.c.
lymphomas, tumors were minced and treated with collagenase and DNase as described 29 .
Id-specific CD4 + T cells
Naïve Id-specific T cells were isolated from LN and spleen of TCR-transgenic or TCRtransgenic SCID mice by magnetic beads, as described above. 17 . To obtain Th1 or Th2 cells, LN cells from TCR-transgenic or TCR-transgenic SCID mice were set up in culture (5 x 10 5 / ml) together with BALB/c spleen cells (2.5 x 10 6 / ml), synthetic 91-107 Id-( 2 315 ) peptide (1 µg/ml), recombinant mouse IL12 (2ng/ml, R&D Systems, Minneapolis, MN) and anti IL4
(11B11 mAb, 1 µg/ml) for Th1 induction; or IL4 (20 U/ml) for Th2 induction. T cells were expanded after several days and used after one or two 10 day cycles. The Id ( 2 315 )-specific 7A10B2 Th1 clone has been described 18 . Complete tissue culture medium was RPMI 1640 with 10% FCS (Gibco) and supplements 30 .
Antibodies and flow cytometry
The following commercially available mAbs were used, conjugated with either FITC, produced by a hybridoma from a 2 315 transgenic mouse served as a standard (BB, unpublished).
Apoptosis assays
Apoptosis was measured by a modified JAM-assay 32 . Tumor cells were cultured in the presence of [methyl- in their sera (average 100 ng/ml) and 6/14 mice had undetectable levels (Fig. 1B) . Thus, the resistance of TCR-transgenic SCID mice against a tumor challenge with F9 ( Fig. 1A ) was paralleled by a significant reduction in amounts of Id + Ig in serum (Fig. 1B) .
Results
Id
Id-specific TCR-transgenic mice on a nonleaky Rag2 -/-background are protected against Id + B lymphoma SCID mice are known to be leaky; in our TCR-transgenic SCID colony ~25% of adult mice had 10 -400 µg/ml IgM in serum while the remainder were negative 17 . We have also detected very low frequencies of endogenous TCR rearrangement and expression in these mice (unpublished). We therefore repeated the tumor challenge experiment, now injecting (Fig. 1A) . To test this possibility, we did a number of transfer experiments.
In the first set of experiments ( Fig. 3A and B within the first 35 days (Fig. 4) . By contrast, only 1 out of 12 mice reconstituted with Idspecific CD4 + T cells on day 0 or day 3 developed a tumor within 120 days. Protection by transfer on day 6 was less impressive with 2/6 mice developing rapidly growing tumors within 30 days (Fig. 4) . When Id-specific CD4 + cell transfer was delayed until days 10, 13 or 17 after cell ratio 2:1; volume ratio 100:1). In single cell suspensions derived from the tumors, Idspecific CD4 + T cells were more frequent, more activated (CD69 + ) and had a more blastlike appearance in F9 compared to F55 tumors (Fig. 5) . had not received T cells (Fig. 6C ) or in Id -F55 tumors in recipients of T cells (Fig. 6D) . The occurrence of neutrophils as a sign of inflammation was therefore dependent on both injection of Id-specific T cells and Id-expression of tumor cells. Further, we analyzed if Id-specific CD4 + T cells could be found in F9 tumors in T cell-injected mice. Indeed, some few TCR transgenic GB113 + T cells were found infiltrating the F9 tumors, and in some cases were found in direct contact with F9 cells (Fig. 6E and data not shown).
Infiltration of Id-specific T cells and neutrophils in inflamed Id
Memory but not naïve Id-specific CD4 + T cells kill Id + B lymphoma cells
The experiments described above suggest that Id-specific CD4 + T cells kill Id + B lymphoma cells in vivo. We proceeded to test this in vitro. F9 (Id + ) and F55 (Id -) were tested in a 3 H-TdR release assay (JAM-assay) for susceptibility to killing by Id-specific CD4 + T cells (Fig. 7) .
This assay measures release of 3 H-TdR -labeled DNA fragments from cells, due to apoptosis.
Previously unstimulated naïve T cells from ordinary TCR-transgenic mice were unable to kill lymphoma cells (Fig. 7) , as were T cells from TCR-transgenic SCID mice or even purified A concern for application in the clinic is that in vitro expansion of Id-specific CD4 + T cells prior to infusion might create memory phenotype T cells that less efficiently home to sites of B lymphoma growth. On the other hand, in the melanoma study 34 
